Company looks forward to further strengthening our position in the pharmaceutical sector, Swapnil Shah, MD, said.
MUMBAI, Dec 30 (The CONNECT) – Shares of Senores Pharmaceuticals Limited made a healthy debut on the exchanges, listing at a 53.45% premium.
The scrip listed Rs 593.70 per share on BSE, a premium of 51.84% and Rs 600 per share on NSE, a premium of 53.45%. The company’s share price closed at Rs 557.80 per share on the BSE, a 42.66% premium, and at Rs 562 per share on the NSE, a 43.73% premium.
As per NSE, the total quantity traded stood at 142.34 lakh shares, on BSE the total Quantity stood at 10.97 lakh shares. Total Turnover (BSE+NSE) on Day 1 stood at Rs 887.72 crore.
Swapnil Shah, MD – Senores Pharmaceuticals Ltd (pictured) said “We are deeply grateful to all our investors for their trust and support, which has been instrumental in helping us achieve this significant milestone. Today, as we list Senores Pharma, we recognize the confidence you have placed in our vision and our ability to execute. This listing marks a new chapter in our growth journey, and we remain committed to delivering long-term value to all stakeholders. We look forward to continuing to build on our success and further strengthening our position in the pharmaceutical sector.”
The Market Capitalization of the Company at today’s closing price stood at Rs. 2,568.87 Crore as per BSE and Rs. 2,558.21 Crore as per NSE.
Senores Pharmaceuticals identifies, develops, and manufactures a wide range of specialty and complex pharmaceutical products, making it a preferred partner for key customers. By leveraging data analytics, research, and its experienced management, the company strategically targets underpenetrated molecules in both Regulated and Emerging Markets. Its strong R&D capabilities enable the development of differentiated products, with a focus on quality and complex molecules. The company has built a robust pipeline, demonstrated through partnerships in the US, Canada, and the UK with major pharmaceutical companies such as Prasco LLC, Jubilant Cadista Pharmaceuticals, and Cipla USA Inc.
The Company primarily focused on Regulated Markets in the US, Canada, and the UK, also has a presence in 43 Emerging Markets. Its business operates under two models: Marketed Products (including ANDA and sourced products) and contract manufacturing (CDMO/CMO). The company’s portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline.
